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Abstract 
Alzheimer’s disease (AD) is the most common type of dementia. The cause of the 
disease is unknown, but a substantial amount of evidence suggest that the disease is 
started by an imbalance in the production and clearance of the protein amyloid-, 
which then starts a cascade of neurodegenerative events leading to cognitive 
symptoms. Biomarkers in cerebrospinal fluid (CSF, amyloid- and tau) reflecting the 
pathological changes in AD can be seen as early as 10-20 years before the clinical 
diagnosis. Pathological levels of the known CSF AD biomarkers in cognitively normal 
individuals can be seen frequently in older adults and this is called preclinical AD. 
This thesis explores different CSF biomarkers for AD and cognition in older adults in 
the preclinical phase of AD using a research framework classification system for 
preclinical AD- the so called ATN system. Study I explores cognition in older adults 
with preclinical AD, using the ATN classification system. We investigated the 
hypothesis that individuals with positive AD biomarkers would have lower cognitive 
test scores than those without biomarkers, and we show this for some tests primarily in 
the memory domain. However, the groups with and without biomarkers performed 
similarly in most tests. Study II investigates the relationship between cognition and the 
neurodegeneration biomarker neurofilament light protein (NfL) and the synaptic 
degeneration biomarker neurogranin (Ng). We investigated the hypothesis that 
individuals with high levels of the biomarkers NfL and Ng would have subtle 
cognitive decline compared to those with normal levels of these biomarkers. We found 
that this was true in a few cognitive tests, however, in most of the tests the groups with 
and without high levels of NfL and Ng performed similarly. Study III investigates the 
levels of the biomarkers NfL and Ng in the ATN groups in cognitively normal older 
adults. We found that individuals with neurodegeneration (tau pathology) had higher 
levels of NfL and Ng, but we did not find any difference in NfL or Ng levels in 
participants with amyloid pathology compared to those without amyloid pathology. 
This suggests that older adults with T-tau pathology have increased axonal and 
synaptic damage. In conclusion, the results from this thesis suggest that the known 
CSF biomarkers for AD and synaptic and neurodegeneration could be valuable 
biomarkers in the earliest phase of AD. 
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